We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This note sets out the methodology used to select the 16 projects identified for funding through the £100 million we set aside for culture in the third round of the Levelling Up Fund (LUF).
As with any medicine, the MHRA will keep the safety and effectiveness of imlunestrant tosylate under close review.
Product Safety Report for Louvolite Perfect Fit Roller and Vision Blinds Chain Tidy presenting a risk of strangulation.
Julie Lennard has been the Chief Executive Officer (CEO) of DVLA since March 2018. Career As CEO, Julie leads the digital and business transformation of one of the UK’s biggest multi-channel service organisations, with more than 52 million customers, more...
Summary of the latest safety advice for medicines and medical device users
Cases of pancreatitis, with or without sphincter of Oddi spasm, have been reported in patients taking eluxadoline. Some cases have resulted in hospitalisation and death, primarily in patients who have undergone cholecystectomy.
Levonorgestrel-releasing intrauterine systems should always be prescribed by brand name because products have different indications, durations of use, and introducers.
A review of the benefits and risks of alemtuzumab (including fatal reactions) in the treatment of multiple sclerosis has now concluded and recommended a revised indication, additional contraindications, and strengthened monitoring requirements before, during and after treatment. Patients offered alemtuzumab...
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).